News

Jul 25, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that LIVMARLI® (maralixibat oral solution) has been authorized by Health Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230725391772/en/ LIVMARLI (maralixibat oral solution) (Graphic: Business Wire) ALGS…

Jul 17, 2023 Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal®Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestonesMirum announces concurrent private placement of $210 million, funding upfront paymentExpands Mirum’s leadership in rare liver disease with two commercial…

Jul 10, 2023 FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 44,850 shares of common stock and 22,430 restricted stock units (“RSUs”) to ten new employees under Mirum’s 2020…

06/30/2023 IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Therapeutics Forum. SVB Securities Therapeutics ForumDate: Tuesday, July…

06/26/2023 IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has been added to the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual…

06/15/2023 IRVINE, Calif., June 15, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present four posters at the 2023 Mitochondrial Medicine Symposium. The event, which is hosted by…